Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
AI-driven biotech Pathos AI has corralled a $237 million Series E at a $3 billion valuation, the New York-based company said on Wednesday. The large fundraise comes in below the $300 million that the biotech ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.